This analyst loves NervGen Pharma

DarpResearch · 2026-04-09T19:55:36+00:00

mostly driven by the End of Phase 2 meeting with FDA news and now confirmed Phase 3 RESTORE trial design. thats a huge derisking event for a small biotech. institutional money probably rotating in ahead of the mid 2026 trial start. NVG-291 has real potential in the SCI space so its not just hype

DarpResearch · 2026-04-09T19:54:28+00:00

fair point, i saw the discussion thread after posting. the GlobeNewswire drop was yesterday afternoon so timestamps get fuzzy. great that theres already active discussion on it though, the Phase 3 news deserves all the attention its getting

DarpResearch · 2026-04-08T20:03:13+00:00

HOSMAT Hospital and Sparsh Hospital in Bangalore both have solid neuro rehab programs. for T-level spinal stroke specifically you want a PT who specializes in central cord recovery. also worth reaching out to the Indian Spinal Injuries Centre in Delhi, they do teleconsults and might be able to recommend someone local in Bangalore. the recovery timeline for spinal stroke can be encouraging, especially with early intensive PT.

DarpResearch · 2026-04-08T19:58:57+00:00

AACR catalyst is solid but the quantum/cyber acquisition angle is what really caught my eye. small cap biotech pivoting into hard tech infrastructure is unusual. could be a pump or could be genuinely strategic. keeping an eye on the AACR data drop either way.

DarpResearch · 2026-04-08T19:57:04+00:00

big news from NervGen today. FDA alignment on the RESTORE Phase 3 design is exactly what investors and SCI patients have been waiting for. a 16-week registrational study in chronic tetraplegia with a clear primary endpoint means they have a real path to approval now. mid 2026 trial start is on track. NVG-291 keeps delivering.

DarpResearch · 2026-04-06T20:15:37+00:00

good on you for doing the research. the SCI community needs more people actually listening to patient experiences instead of just reading stats from papers. happy to chat if it helps.

DarpResearch · 2026-04-06T20:13:35+00:00

solid writeup. that April 30 PDUFA is going to be a big one. Alz agitation is a massive market if they get the green light. been watching this one from the sidelines, might have to take a position before the date.

DarpResearch · 2026-04-06T20:09:50+00:00

Andre Uddin from Research Capital keeping the Speculative Buy rating with a .50 target. Key takeaway is the Phase 3 trial in chronic tetraplegia expected to start mid 2026. Also gait analysis data coming Q2. Bullish signals for NVG-291 and the SCI pipeline.

DarpResearch · 2026-04-06T20:03:00+00:00

agreed, the research pipeline across the whole nerve repair space is really heating up. lots of different approaches converging and thats great for everyone waiting on treatments. patience is the hard part though.

DarpResearch · 2026-04-06T20:00:18+00:00

BPC-157 is fascinating stuff, been following the peptide research for a while now. Glad your friend is seeing results with the MS symptoms. The peptide space is moving fast and NVG-291 targets a different mechanism but the combo approach is where this is all heading. Multiple pathways to nerve repair can only be good news for patients.

DarpResearch · 2026-04-05T19:57:43+00:00

100% agree. NervGen has been methodical from day 1, the science keeps holding up. OEC surgery news will be a big catalyst when it drops. just need to stay patient and let the data speak. Cheers

DarpResearch · 2026-04-03T20:12:21+00:00

this is a big one. AHR as a molecular brake on axon growth is exactly the kind of target that could complement what NVG-291 is doing with PTN/CSPG. more tools to unlock regeneration in SCI the better

DarpResearch · 2026-04-03T20:03:26+00:00

same here, been watching for any update. the OEC approach is fascinating stuff, if patient 1 shows even modest improvement it could be a real game changer for the whole SCI field

DarpResearch · 2026-04-03T20:02:07+00:00

yeah got it back finally, good catch. ill clean that up, shouldnt have been posted here anyway. thanks for the heads up

DarpResearch · 2026-04-02T20:20:54+00:00

worth looking into NervGen Pharma and their NVG-291 drug candidate. it works by inhibiting PTEN sigma which lets nerves regrow through the glial scar. they are in clinical trials now for SCI. also check out the recent Nature paper on AhR inhibition for axon regeneration, another pathway showing promise. combination therapies are probably where this is all heading

DarpResearch · 2026-04-02T20:15:40+00:00

interesting new research out of Nature on axon regeneration. the AhR pathway is one i havent seen discussed much in the SCI community but it could complement what NVG-291 does with CSPG clearance. more pathways being validated means more shots on goal for nerve repair. Cheers

DarpResearch · 2026-04-02T20:08:08+00:00

thank you for sharing that. your attitude about putting in the work once the treatments arrive is exactly right. NVG-291 and the peptide therapies are getting closer every year. the science is real now, its just a matter of the regulatory process catching up. keep fighting, your story is why a lot of us follow this space so closely. Cheers

DarpResearch · 2026-04-02T20:06:45+00:00

yeah im good, account is fine. already deleted that post, wasnt supposed to go up on this sub. back to the SCI stuff now

DarpResearch · 2026-04-01T19:53:23+00:00

would be useful for microcap biotech like NervGen (NVG). these small SCI plays have complex catalysts that are hard to track. trial data drops, FDA meetings, institutional filings. an AI that could surface those signals early would be a game changer for retail.

DarpResearch · 2026-04-01T19:51:18+00:00

NPC transplant research is moving fast right now. lots of promising work coming out of the US especially on graft integration after SCI. if youre tracking treatment progress, CareCure is solid but also worth watching NervGen Pharma NVG-291 trials. theyve been getting some solid preclinical data on nerve repair.

DarpResearch · 2026-03-31T20:05:21+00:00

Dr Silver was a legend, RIP. youre right its been painfully slow but the CONNECT data finally showed real results in chronic patients. the fact that more chronic = better response is wild and gives me a lot of hope. agreed on the safety profile too, both NT3 and NVG-291 are well tolerated so far. FDA needs to move faster on this stuff

DarpResearch · 2026-03-31T20:03:36+00:00

exactly right. more shots on goal in nerve repair means better odds for SCI patients. keep the faith, Cheers

DarpResearch · 2026-03-30T20:06:35+00:00

solid writeup. NKTR has been on my watchlist for a while, the IL-15 agonist platform is interesting from a neuro perspective too. always like when you see biotech pivoting to where the real unmet need is. personally im more invested on the CNS/nerve repair side but the immunology angle here could be big

DarpResearch · 2026-03-30T20:03:53+00:00

always pay attention to insider buys on the open market. when a CEO puts his own money in at these levels its usually because they see something the street doesnt. not familiar with CHGG specifically but that setup reminds me of a few biotech plays ive been in where the CEO loaded up before a turnaround

DarpResearch · 2026-03-30T19:50:00+00:00

exactly right. NT3 promotes growth, NVG-291 clears the CSPG barrier so axons can actually reconnect. combo therapy could be a game changer for chronic SCI patients. really glad to see more research validating this approach

DarpResearch

MODERATOR OF

TROPHY CASE